openPR Logo
Press release

Investigation for Long-Term Investors in shares of Correvio Pharma Corp. (NASDAQ: CORV) announced

04-08-2020 03:19 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Correvio Pharma Corp. (NASDAQ: CORV) shares.

An investigation on behalf of current long term investors in Correvio Pharma Corp. (NASDAQ: CORV) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Correvio Pharma Corp.

Investors who are current long term investors in Correvio Pharma Corp. (NASDAQ: CORV) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: CORV stocks follows a lawsuit filed against Correvio Pharma Corp. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: CORV stocks, concerns whether certain Correvio Pharma Corp. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that the data supporting the Resubmitted NDA for Brinavess did not minimize the significant health and safety issues observed in connection with the drug's original NDA, that the foregoing substantially diminished the likelihood that the FDA would approve the Resubmitted NDA, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Correvio Pharma Corp. (NASDAQ: CORV) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation for Long-Term Investors in shares of Correvio Pharma Corp. (NASDAQ: CORV) announced here

News-ID: 2002737 • Views: 291

More Releases from Shareholders Foundation

NS8 Inc. Former Employee Alert: Investigation over possible Violations of Securi …
An investigation was announced over potential securities laws violations by NS8 Inc. and certain of its directors and officers in connection with certain financial statements. Former employees of NS8 Inc. should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether certain statements by NS8 Inc. regarding its business, its prospects and its operations were materially false and misleading
Update in Lawsuit for Investors in shares of The RealReal, Inc. (NASDAQ: REAL)
A lawsuit is pending for investors in The RealReal, Inc. (NASDAQ: REAL) over alleged violations of Federal Securities Laws by The RealReal, Inc. in connection RealReal’s June 2019 initial public stock offering (the “IPO”). Investors who purchased shares of The RealReal, Inc. (NASDAQ: REAL) have certain options and for certain investors are short and strict deadlines running. Deadline: January 24, 2020. NASDAQ: REAL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Deadline on Sept. 28th upcoming in Lawsuit for Investors in shares of FirstEnerg …
The Shareholders Foundation announced that a deadline is coming up on September 28, 2020 in the lawsuit filed for certain investors of FirstEnergy Corp. (NYSE: FE) over alleged securities laws violations by FirstEnergy Corp. Investors who purchased shares of FirstEnergy Corp. (NYSE: FE) have certain options and there are strict and short deadlines running. Deadline: September 28, 2020. NYSE: FE stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Investigation announced for Long-Term Investors in shares of Co-Diagnostics, Inc …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Co-Diagnostics, Inc.. Investors who are current long term investors in Co-Diagnostics, Inc. (NASDAQ: CODX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: CODX stocks follows a lawsuit filed against Co-Diagnostics, Inc over

All 5 Releases


More Releases for Correvio

Scleroderma Therapeutics Market Growth, Trends, Industry Analysis and Forecast - …
The global scleroderma therapeutics market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, rising investment in the R&D of drugs for its treatment, the emergence of new novel therapies, and new product launches are some of the key factors contributing to the growth of the scleroderma therapeutics market across the globe. According to the American College of Rheumatology, scleroderma is a relatively rare
Innoplexus welcomes Dr. Sven Niedner as the Chief Operating Officer and Juergen …
Innoplexus announces the joining of two members in the leadership team, Dr. Sven Niedner as the Chief Operating Officer and Juergen Raths, MD as Life Sciences Head both effective from August 1st 2017. Dr. Gunjan Bhardwaj, Founder & CEO and Gaurav Tripathi, CTO of Innoplexus discussing about the expertise that Dr. Sven Niedner and Juergen Raths, MD would bring to Innoplexus said: "Both add experience and understanding of how companies scale